SAN FRANCISCO--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce the results of separate analyses of KRAS gene mutations and TS and RRM1 gene expression in non-small cell lung cancer (NSCLC) during the 13th World Conference on Lung Cancer, which will be held July 31 to August 4. Results will provide insights into which patient subtypes are most likely to benefit from the commonly prescribed chemotherapies pemetrexed and gemcitabine.
